ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tradipitant

Also written as “Tradipitant”, “VLY-686” and “LY686017”.

Its studies are mostly in Motion Sickness · Gastroparesis · Dermatitis, Atopic · Pruritus · Nausea, led by 2 companies.

Drug pageTradipitant: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 13, 201819 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticalsits history only173 open or runningphase 3since Jun 13, 2018Aug 2, 2013Dec 1, 2026phase 3 · NCT07446439
Eli Lilly20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead

Also a collaborator on its studies: Cross Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2005First study: phase 2 study in Phobia, SocialFirst studyNCT00191022 · 185 enrolled · United States
  2. Dec 5, 2008Phase 2 study in AlcoholismNCT00805441 · 190 enrolled · United States

TargetBeta

TACR1 →read by rule
“An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
AprepitantruleMerckphase 427
elinzanetantruleBayerphase 324
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 2 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00805441Alcoholism · United States2CompletedJul 2009190
NCT00191022Phobia, Social · United States2Completed185

How it is read

Names in the registry

  • “Tradipitant”, 13 entries
  • “VLY-686”, 2 entries
  • “LY686017”, 2 entries
  • “Open Label Tradipitant”, 1 entry
  • “VLY-686 (Tradipitant)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.